Loading the section…

ENGN: financial statements from SEC — TradeAlmanac

ENGN

enGene Therapeutics Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	30/04/2026	31/01/2026	31/07/2025	30/04/2025	31/01/2025	31/07/2024
Research and development	22M	22M	23M	20M	20M	12M
Selling, general and administrative	10M	9M	7M	7M	7M	5M
Operating expenses	32M	31M	30M	27M	27M	17M
Operating income	−32M	−31M	−30M	−27M	−27M	−17M
Pre-tax income	−30M	−30M	−29M	−26M	−25M	−14M
Income tax	0	0	239,000	240,000	18,000	−29,000
Net income	−30M	−30M	−29M	−26M	−25M	−14M
Earnings per share	−0.43	0.44	0.57	0.51	0.48	0.32
Earnings per share, diluted	−0.43	0.44	0.57	0.51	0.48	0.32
Weighted average shares	70M	67M	51M	51M	51M	44M
Weighted average shares, diluted	70M	67M	51M	51M	51M	44M

Balance sheet

Metric	30/04/2026	31/01/2026	31/10/2025	31/07/2025	30/04/2025	31/01/2025	31/10/2024	31/07/2024
Cash and equivalents	30M	37M	50M	33M	58M	62M	173M	258M
Short-term investments	229M	239M	144M

Cash flow

Metric	31/01/2026	31/01/2025
Operating cash flow	−29M	−26M
Depreciation and amortisation	189,000	102,000
Share-based compensation	3M	2M
Capital expenditure	153,000	299,000
Investing cash flow	−126M	−85M
Financing cash flow	142M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator